The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation

Research output: Contribution to journalArticle

Abstract

BACKGROUND We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. METHODS Data were retrospectively analyzed in 96 patients with biochemically relapsed prostate cancer (BRPC) treated with IAD since 1995. IAD consisted of LHRH-agonists ± antiandrogen given usually at PSA threshold (ng/ml) of 10-20, for 6-9 months. Cycles were repeated until the development of castration resistance. Mixed effects model was used to study PSADT change over cycles. Multivariate cox regression model was used to identify outcome-associated variables. RESULTS Patients received a mean of 2.8 treatment cycles over a mean follow-up time of 71 months. Fifty-seven (59%) remain on treatment and 39 (41%) developed PSA refractoriness (n = 8) or positive scans (n = 31). First off treatment interval PSADT (median 2.3 months) was significantly shorter than the baseline (median 7.34) but remained stable in subsequent cycles. Off treatment interval PSADT adjusted for testosterone recovery (median 3.7) was significantly longer than that based on all PSA determinations (median 2). Factors associated with disease progression were pre-treatment PSADT (≥6 vs.

Original languageEnglish (US)
Pages (from-to)1608-1615
Number of pages8
JournalProstate
Volume71
Issue number15
DOIs
StatePublished - Nov 2011

Fingerprint

Androgens
Disease Progression
Prostatic Neoplasms
Therapeutics
Androgen Antagonists
Castration
Proportional Hazards Models
Gonadotropin-Releasing Hormone
Testosterone

Keywords

  • disease progression
  • intermittent androgen deprivation therapy
  • non-metastatic biochemically relapsed prostate cancer
  • PSA doubling time
  • serum testosterone

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

@article{2438764cf66d4846b7429c81af8756c9,
title = "The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation",
abstract = "BACKGROUND We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. METHODS Data were retrospectively analyzed in 96 patients with biochemically relapsed prostate cancer (BRPC) treated with IAD since 1995. IAD consisted of LHRH-agonists ± antiandrogen given usually at PSA threshold (ng/ml) of 10-20, for 6-9 months. Cycles were repeated until the development of castration resistance. Mixed effects model was used to study PSADT change over cycles. Multivariate cox regression model was used to identify outcome-associated variables. RESULTS Patients received a mean of 2.8 treatment cycles over a mean follow-up time of 71 months. Fifty-seven (59{\%}) remain on treatment and 39 (41{\%}) developed PSA refractoriness (n = 8) or positive scans (n = 31). First off treatment interval PSADT (median 2.3 months) was significantly shorter than the baseline (median 7.34) but remained stable in subsequent cycles. Off treatment interval PSADT adjusted for testosterone recovery (median 3.7) was significantly longer than that based on all PSA determinations (median 2). Factors associated with disease progression were pre-treatment PSADT (≥6 vs.",
keywords = "disease progression, intermittent androgen deprivation therapy, non-metastatic biochemically relapsed prostate cancer, PSA doubling time, serum testosterone",
author = "Daniel Keizman and Peng Huang and Emmanuel Antonarakis and Victoria Sinibaldi and Carducci, {Michael A} and Denmeade, {Samuel R} and Kim, {Jenny J.} and Janet Walczak and Mario Eisenberger",
year = "2011",
month = "11",
doi = "10.1002/pros.21377",
language = "English (US)",
volume = "71",
pages = "1608--1615",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "15",

}

TY - JOUR

T1 - The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation

AU - Keizman, Daniel

AU - Huang, Peng

AU - Antonarakis, Emmanuel

AU - Sinibaldi, Victoria

AU - Carducci, Michael A

AU - Denmeade, Samuel R

AU - Kim, Jenny J.

AU - Walczak, Janet

AU - Eisenberger, Mario

PY - 2011/11

Y1 - 2011/11

N2 - BACKGROUND We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. METHODS Data were retrospectively analyzed in 96 patients with biochemically relapsed prostate cancer (BRPC) treated with IAD since 1995. IAD consisted of LHRH-agonists ± antiandrogen given usually at PSA threshold (ng/ml) of 10-20, for 6-9 months. Cycles were repeated until the development of castration resistance. Mixed effects model was used to study PSADT change over cycles. Multivariate cox regression model was used to identify outcome-associated variables. RESULTS Patients received a mean of 2.8 treatment cycles over a mean follow-up time of 71 months. Fifty-seven (59%) remain on treatment and 39 (41%) developed PSA refractoriness (n = 8) or positive scans (n = 31). First off treatment interval PSADT (median 2.3 months) was significantly shorter than the baseline (median 7.34) but remained stable in subsequent cycles. Off treatment interval PSADT adjusted for testosterone recovery (median 3.7) was significantly longer than that based on all PSA determinations (median 2). Factors associated with disease progression were pre-treatment PSADT (≥6 vs.

AB - BACKGROUND We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. METHODS Data were retrospectively analyzed in 96 patients with biochemically relapsed prostate cancer (BRPC) treated with IAD since 1995. IAD consisted of LHRH-agonists ± antiandrogen given usually at PSA threshold (ng/ml) of 10-20, for 6-9 months. Cycles were repeated until the development of castration resistance. Mixed effects model was used to study PSADT change over cycles. Multivariate cox regression model was used to identify outcome-associated variables. RESULTS Patients received a mean of 2.8 treatment cycles over a mean follow-up time of 71 months. Fifty-seven (59%) remain on treatment and 39 (41%) developed PSA refractoriness (n = 8) or positive scans (n = 31). First off treatment interval PSADT (median 2.3 months) was significantly shorter than the baseline (median 7.34) but remained stable in subsequent cycles. Off treatment interval PSADT adjusted for testosterone recovery (median 3.7) was significantly longer than that based on all PSA determinations (median 2). Factors associated with disease progression were pre-treatment PSADT (≥6 vs.

KW - disease progression

KW - intermittent androgen deprivation therapy

KW - non-metastatic biochemically relapsed prostate cancer

KW - PSA doubling time

KW - serum testosterone

UR - http://www.scopus.com/inward/record.url?scp=80053201964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053201964&partnerID=8YFLogxK

U2 - 10.1002/pros.21377

DO - 10.1002/pros.21377

M3 - Article

C2 - 21432863

AN - SCOPUS:80053201964

VL - 71

SP - 1608

EP - 1615

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 15

ER -